


Oncology
2025-05-01

Traditional CAR-T therapies depend on costly, labor-intensive ex vivo engineering of patient- or donor-derived T cells. Recent innovations in in vivo CAR-T generation—using lentiviral vectors to directly program T cells within the body—promise a faster, more economical alternative. However, preclinical testing of these strategies requires immunodeficient mouse models expressing human-specific targets, which are frequently hindered by graft-versus-host disease (GvHD), shortening treatment windows and confounding results.
More infomation about blogs

Let us know which event you're attending and we'd be happy to connect with you.
This website will store cookies on your computer. These cookies are used to collect information about how you interact with this website and enable us to remember you. We use this information to improve and customize your browsing experience, as well as to analyze and collect relevant data and metrics about visitors on this website and other platforms. For more information about the cookies we use, please refer to our privacy policy
If you decline, your information will not be tracked when visiting this website. A cookie will be used in your browser to remember your preference settings that you have not accepted.
